Vaccitech (NASDAQ:VACC) Price Target Cut to $22.00 by Analysts at HC Wainwright

Vaccitech (NASDAQ:VACC – Get Rating) had its price objective decreased by investment analysts at HC Wainwright from $23.00 to $22.00 in a research note issued on Thursday, The Fly reports. HC Wainwright’s price target points to a potential upside of 447.26% from the company’s previous close.

Separately, Zacks Investment Research lowered shares of Vaccitech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.00.

Vaccitech stock opened at $4.02 on Thursday. The stock has a market capitalization of $149.51 million and a PE ratio of -3.72. Vaccitech has a twelve month low of $2.97 and a twelve month high of $17.99. The company has a 50 day moving average of $5.16 and a 200-day moving average of $8.67.

Vaccitech (NASDAQ:VACC – Get Rating) last released its quarterly earnings results on Friday, March 25th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Vaccitech had a negative net margin of 7,416.85% and a negative return on equity of 25.01%. On average, equities research analysts forecast that Vaccitech will post -1.43 EPS for the current fiscal year.

In other news, Director Joseph Scheeren purchased 10,000 shares of the company’s stock in a transaction on Friday, April 1st. The shares were purchased at an average cost of $5.09 per share, with a total value of $50,900.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $15,270. The transaction was disclosed in a filing with the SEC, which is available through this link.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Liontrust Investment Partners LLP bought a new position in shares of Vaccitech in the third quarter valued at about $9,444,000. Johns Hopkins University bought a new position in shares of Vaccitech in the fourth quarter valued at about $1,200,000. Morgan Stanley bought a new position in shares of Vaccitech in the second quarter valued at about $284,000. Finally, Ghisallo Capital Management LLC raised its position in shares of Vaccitech by 106.3% in the third quarter. Ghisallo Capital Management LLC now owns 20,625 shares of the company’s stock valued at $325,000 after purchasing an additional 10,625 shares during the period. 19.76% of the stock is currently owned by hedge funds and other institutional investors.

About Vaccitech (Get Rating)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.

Featured Stories